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Summary
Objective: The hallmark in osteoarthritis (OA) is the loss of proteoglycans (PGs) in articular cartilage (AC). Xylosyltransferase I (XT-I) cata-
lyzes the transfer of xylose to serine residues in the core protein and initiates the biosynthesis of PGs in AC. The XYLT-II gene encodes a
highly homologous protein but its biological function is not yet known. Here we investigate for the ﬁrst time genetic variations in the XYLT-
genes and serum XT-I activities and their implication in OA.
Methods: Denaturing high-performance liquid chromatography (DHPLC) was used for the screening of the XYLT-genes in 49 OA patients. For
a detailed characterization of XT-I amino acid exchanges we performed recombinant expression of XT-I mutants in insect cells. Furthermore,
the XT activity was measured in the patients’ serum.
Results: The variation c.1569C > T (XYLT-II) occurs with a signiﬁcantly higher frequency in younger OA patients in comparison with the older
ones (P< 0.001) and the controls (P< 0.02). Furthermore, signiﬁcantly higher serum XT activities were found in patients with a long disease
duration of OA (P< 0.04). The recombinant XT-I mutants p.P385L and p.I552S had reduced enzymatic activity (85% and 74%) compared with
the wildtype (wt).
Conclusions: Our ﬁndings indicate a correlation of the c.1569 T-allele in XYLT-II with an earlier manifestation of OA and that the serum XT
activity is a potential biochemical marker for staging and monitoring the progression of AC damage in OA. Comparison of XT-I activity in mu-
tant enzymes in vivo and in vitro revealed that heterozygous mutations are not involved in OA.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: AC Articular cartilage, bFGF Basic ﬁbroblast growth factor, CS Chondroitin sulfate, CSPG Chondroitin sulfate proteoglycan,
DHPLC Denaturing high-performance liquid chromatography, ECM Extracellular matrix, GAG Glycosaminoglycan, KS Keratan sulfate, OA
Osteoarthritis, PG Proteoglycan, RFLP Restriction fragment length polymorphism, SNP Single nucleotide polymorphism, UTR Untranslated
region, wt Wildtype, XT Xylosyltransferase enzyme, XYLT Xylosyltransferase gene.Introduction
Osteoarthritis (OA) is a frequent degenerative joint disease
characterized by progressive loss of articular cartilage (AC)
and remodeling of subchondral bone with sclerosis1. It is
believed that OA is the consequence of mechanical and
biochemical events that result in an imbalance between
the synthesis and the degradation of AC matrix2. Aging, ge-
netic, hormonal and mechanical factors are contributors to
the onset and progression of this slowly developing multi-
factorial disorder3. Genes which regulate the formation,
degradation and repair of AC and subchondral bone metab-
olism may determine the occurrence of OA4. The central
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zation of AC, which mainly consists of chondrocytes and
extracellular matrix (ECM). The ECM is composed of colla-
gen ﬁbrils (mainly collagen type II) and proteoglycans
(PGs), which are synthesized by the chondrocytes5. The
predominant PG present in cartilage is the large chondroitin
sulfate proteoglycan (CSPG) aggrecan6. Aggrecan consists
of a core protein, to which about 100 chondroitin sulfate
(CS) chains and 20e30 keratan sulfate (KS) chains were
covalently attached7. A number of aggrecan molecules
are bound with the help of a link protein to a central hyalur-
onan core molecule, forming large aggregates8. An impor-
tant role in the development of OA is that osteoarthritic
cartilage has a lower capacity for aggregate formation and
therefore a decreased amount of PG aggregates9,10. This
loss may be due to increased degradation, inhibition of bio-
synthesis or an inhibition of PG retention due to deﬁcits in
hyaluronan. Furthermore, changes in charge density were
observed11.
The glycosylation of the core protein in CS containing
PGs is initiated by xylosyltransferase I (XT-I, EC 2.4.2.26).2
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selected serine residues in the PG-core protein. This is
the initial and apparently rate-limiting step in the formation
of the common tetrasaccharide linkage region (eGlcAe
GaleGaleXyleSer) to which many disaccharides’ repeats
are attached as part of the biosynthesis of PGs7. CS is an
unbranched, polydisperse, complex glycosaminoglycan
(GAG) with polysaccharide chains composed mainly of
disaccharide units of alternating N-acetyl-D-galactosamine
and D-glucuronate residues. The disaccharide elongation
of the linker is followed by extensive modiﬁcations of
CS-GAGs through a variety of different enzymes. This
leads to the presence of functionally important, negatively
charged sulfate groups12,13.
The XYLT-II gene codes for a protein highly homologous
to the XT-I. The C-terminal regions of both proteins, where
the catalytic domain was found to be located in glycosyl-
transferases, are highly conserved14e16. These ﬁndings
lead us to conclude that the XYLT-II gene codes for another
XT, although the catalytic activity and the biological function
of XT-II are not yet known15. The very high content of CS-
rich PGs, primarily aggrecan in AC, is responsible for its
compressive features. The hypermetabolic repair response
in early stages and the later observed loss of PGs in oste-
oarthritic cartilage indicated an altered PG metabolism in
OA patients17. XT-I was previously shown to be a regulatory
factor of the CS biosynthesis18. Therefore we hypothesized
that genetic variations in the XT genes are implicated in the
imbalance between synthesis and decomposition of ECM in
OA. This is the ﬁrst report about mutational analysis in the
XYLT-genes in OA patients. The XYLT-I gene is located
on chromosome 16p13.1, consists of 12 exons and extends
over 300 kbp. In contrast the XYLT-II gene is localized on
chromosome 17q21.3-22, comprises 11 exons and spans
only 15 kbp. Furthermore, we determined the XT activities
in serum samples of OA patients in order to evaluate the
validity of XT as a diagnostic marker.
Materials and methods
MATERIALS
High Five insect cells (Trichoplusia ni, BTI-TN-5B1-4)
were purchased from Invitrogen (Groningen, The Nether-
lands), Insect Xpress medium was obtained from Cambrex
(Apen, Germany) and for transfection we used Cellfectin-
Reagenz, also from Invitrogen. The vector pMIB-V5-His,
the horseradish peroxidase-conjugated anti-V5 antibodies
and the primers were all from Invitrogen. We used the Quik-
Change XL Site-Directed Mutagenesis Kit from Stratagene
(La Jolla, CA, USA) for the design of the mutants. HotStar-
Taq-DNA-Polymerase, HiSpeed Plasmid Midi Kit, PCR pu-
rification Kit and QIAamp DNA Blood Mini Kit were
obtained from Qiagen (Hilden, Germany). ProGel-TriseGly-
cin-Gel, TriseGlycin-SDS sample and running buffer and
the ProGel/ProGel P Transferbuffer were bought from
Anamed (Darmstadt, Germany) and NuPAGE Antioxidant
and Reducing Agent were all bought from Invitrogen. Micro-
con 3000 tubes and PVDF membranes were purchased
from Millipore (Eschborn, Germany). UDP-[14C]-xylose
(9.88 kBq/nmol) was obtained from DuPont (Bad Homburg,
Germany), the peptide bFGF (1e24) was from Bachem
(Heidelberg, Germany), 25 mm diameter nitrocellulose
discs were from Sartorius (Go¨ttingen, Germany) and the
scintillation mixture and liquid scintillation counter
LS5000TD were obtained from Beckman Coulter (Fullerton,CA, USA). DNA sequencing was performed using the ABI
Prism Big Dye Terminator v1.1 Cycle Sequencing Kit and
the ABI Prism 310 Genetic Analyzer from Perkin Elmer
(Foster City, CA, USA). Denaturing high-performance liquid
chromatography (DHPLC) was carried out with the DNA
separation column on the Wave System from Transge-
nomic (Omaha, NE, USA). The restriction enzymes were
obtained from New England Biolabs (Beverly, MA, USA)
and from MBI Fermentas (St. Leon-Rot, Germany).
PATIENTS
A total of 49 unrelated OA patients were examined for
genetic variations in the human XYLT-genes and for serum
XT activity (clinical characteristics are shown in Table I).
Furthermore, the detected variations and the XT activity
were also determined in 111e321 non-OA blood donors
(number of controls investigated was dependent on the
localization of the variation). The OA patients included in
this study were diagnosed based on the international crite-
rion and the controls were excluded by the same criterion.
The experimental design was approved by the local ethics
committee, and all patients gave their informed consent. Ge-
nomic DNA was isolated from peripheral blood leukocytes.
POLYMORPHISM SCREENING AND GENOTYPING
Polymorphism screening and genotyping in the XYLT-
genes of OA patients were performed using DHPLC. Primer
sequences, polymerase chain reaction (PCR) conditions,
DHPLC conditions and restriction fragment length polymor-
phism (RFLP) conditions for this analysis were described
previously19. Based on their location and potential effect
on gene function, 15 of the detected variations (ﬁve of
XYLT-I and 10 of XYLT-II) were initially genotyped in the
non-OA control group by DHPLC or RFLP (Table II).
SITE-DIRECTED MUTAGENESIS
Cloning of a soluble N-terminal truncated form of human
XT-I (XT-ID1-148-V5-His) in the vector pCG255 for the re-
combinant expression in the High Five insect cells was pre-
viously described20e22. This vector was used as a template
for inducing four amino acid exchanges in XT-I with the
QuikChange XL Site-Directed Mutagenesis Kit; two of
them (c.1883 and c.2675) were already described19 and
were only detected in Type 1 diabetic patients with a fre-
quency of 1%, c.1154 was previously described but was
also detected in our patients and c.1655 was newly
Table I
Clinical characteristics of Caucasian OA patients
Male Female P-value
n 21 28 e
Age (years) 71.6 7.1 65.8 9.8 0.0260
Age of diagnosis (years) 67.7 8.3 58.8 14.2 0.0138
Duration of OA 3.9 0.9 7.0 8.8 0.2170
Joint involvement
Mean number 1.3 0.6 1.3 0.5 1.0
Hip 13 (62%) 22 (79%) 0.2219
Knee 10 (48%) 13 (46%) 1.0
Finger e 1 (4%) 1.0
Spinal column 5 (24%) e 0.0096
XT activity (mU/L) 1.06 0.17 1.02 0.13 0.3675
Data are means SD, or n.
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Allelic frequencies of detected XYLT-variations in OA patients and blood donors, their effect on the amino acid sequence and their location in
the gene






XYLT-I IVS1-5C >G 5#-UTR ND ND ND
c.343G > T p.A115S Exon 1 Tsp45Ix 4 3.4
IVS2D 6T > C Intron 2 Sequencing 1 ND
IVS2D 29A >G Intron 2 Sequencing 1 ND
IVS3D 10C > T Intron 3 Sequencing 1 ND
IVS3D 30G >C Intron 3 Sequencing 1 ND
IVS4þ 47A >G rs 11075341 Intron 4 DHPLC 56 ND
c.1154C > T p.P385L Exon 5 DHPLC 1 0.5
c.1284C >G Exon 5 DHPLC 12 17.9
c.1655T >G p.I552S Exon 8 LweIx 0 0.2
c.1989T > C rs 12708815 Exon 9 DHPLC 24 34.5
IVS10D 100A >G Intron 10 ND ND ND
c.2631C > T Exon 12 DHPLC 16 17.5
XYLT-II IVS1-86delG 5#-UTR Sequencing 37 ND
IVS1-84G > A rs 9912067 5#-UTR Sequencing 1 ND
c.166G > A p.D56N Exon 2 Eco47Ix 2 2.0
c.177A >G rs 739990 Exon 2 BsaWIk 64 77.1
c.342T >C rs 739989 Exon 2 BsaWIk 64 77.1
c.914C >G rs 12451299 p.T305R Exon 4 Bsu36Ik 74 78.9
IVS6-9T > C Intron 5 Sequencing 2 1.1
IVS6-14_IVS6-13insG Intron 5 MwoIk 2 1.1
c.1216C > T p.R406C Exon 6 Sequencing 1 0
c.1253C > T p.P418L Exon 6 BfuAIk 1 2.2
IVS7þ 81A > C Intron 7 Sequencing 1 ND
c.1569C > T rs 4794136 Exon 8 Msl Ik 49 52.7
c.2402C >G rs 6504649 p.T801R Exon 11 DHPLC 37 40.2
Mutation numbering refers to the cDNA sequences with the A of the ATG translation initiation start site as nucleotide þ1; variations in bold
are new. ND, not determined.
*Numbering of the XT-I variations are based on human cDNA sequence (GenBank accession number NM_022166). Sequence discre-
pancies between the cDNA and the genomic DNA (GenBank accession numbers AC109446, AC099494, AC009152, AC109495) exist.
We detected in our samples at the following positions only the nucleotide of the genomic sequence: IVS1-14: g; c.489: c; c.2850: g;
c.2853: a.
yNumbering of the XT-II variations are based on human cDNA sequence (GenBank accession number NM_022167).
zrs-number is according to data bank (http://www.ensembl.org and http://snpper.chip.org).
xMBI Fermentas.
kNew England BioLabs.identiﬁed in this work in a control person. The sequences of
the mutagenesis primers are listed in Table III. Mutated
DNA was double-stranded sequenced to conﬁrm the nucle-
otide exchange and to ensure that no additional changes
were introduced. The wildtype (wt) and these four mutants
were individually expressed in the High Five insect cells
as described below. At least two vectors encoding each
XT-I variant and two independent transfection experiments
were performed for the analysis of the mutants to ensure re-
producibility of the results. In addition, all vectors encoding
XT-I variants with altered enzyme activity were remodiﬁedto the wt enzyme by site-directed mutagenesis as described
above. These revertants were also expressed in the High
Five insect cells to ensure full restoration of enzyme activity.
HETEROLOGOUS EXPRESSION IN THE HIGH FIVE
INSECT CELLS
Cloning and overexpression of recombinant wt and mu-
tant XT-I in the High Five insect cells were performed as de-
scribed previously20e22. At 96 h post-transfection the
recombinant enzyme containing cell culture medium wasTable III
Mutagenesis primers used for the generation of amino acid mutants derived from pCG255-1, which codes for the soluble rXT-ID1-148-V5-His
Primer Mutation Sequence*
XT-1 c1154t p.P385L 5#-TCC GCG TCA CCC TCT GGA GGA TGG CC-3#
XT-1 anti c1154t 5#-GGC CAT TCT CCA GAG GGT GAC GCG GA-3#
XT-1 t1655g p.I552S 5#-CAA CAA CCT GCG CAG CAC CAA CTG GAA TCG-3#
XT-1 anti t1655g 5#-CGA TTC CAG TTG GTG CTG CGC AGG TTG TTG-3#
XT-1 g1883a p.R628H 5#-CCC GGG CCT GCA CTC CTA CTG GGA-3#
XT-1 anti g1883a 5#-TCC CAG TAG GAG TGC AGG CCC GGG-3#
XT-1 g2675a p.R892Q 5#-GTG GAA CAG GCA CAG AGG AAC GCA GCC T-3#
XT-1 anti g2675a 5#-AGG CTG CGT TCC TCT GTG CCT GTT CCA C-3#
*The changed nucleotide is bold and underlined.
445Osteoarthritis and Cartilage Vol. 14, No. 5collected and clariﬁed by centrifugation at 1500 g for
5 min. The supernant was enriched 50-fold by ultraﬁltration.
SDS-PAGE AND WESTERN BLOT ANALYSES
16.25 mL of concentrated High Five cell culture supernant
was added to 6.25 mL of sample buffer and 2.5 mL Reducing
Agent. The mixture was heated at 90(C for 10 min and SDS-
PAGE was carried out on a 8e16% ProGel-TriseGlycin-Gel
with TriseGlycin-SDS running buffer and Antioxidant. After
size fractionation the proteins were electrophoretically trans-
ferred onto a PVDF membrane for immunodetection using
a semidry electroblotting apparatus. Nonspeciﬁc antibody-
binding sites were blocked with 2% (w/v) bovine serum
albumin (BSA) in 0.1 M TriseHCl, pH 7.2 at room tempera-
ture for 1 h. The membrane was incubated with horseradish
peroxidase-coupled anti-V5 antibodies at 1:500 dilution and
bound antibodies were detected using 4-chloro-1-naphthol.
XT ACTIVITY ASSAY
The method for determination of XT activity is based on
the incorporation of [14C]-D-xylose into an acceptor. For se-
rum XT activity we used silk ﬁbroin23,24, and for the activity
of recombinant enzymes in cell culture supernant we used
the bFGF fragment (1e24)25 as the acceptor. The standard
reaction mixture (100 mL) for the assay contained 50 mL se-
rum or diluted cell culture supernant, 25 mM 4-morpholine-
ethanesulfonic acid (pH 6.5), 25 mM KCl, 5 mM KF, 5 mM
MgCl2, 5 mM MnCl2, 1 mM UDP-[
14C]-D-xylose and 30 mL
solubilized silk ﬁbroin (10 mg/mL) or bFGF (3.125 mM). After
incubation at 37(C for 90 min the reaction mixtures were
placed on nitrocellulose discs. The dried discs were washed
with 10% trichloroacetic acid for 10 min and three times with
1% trichloroacetic acid. Incorporated radioactivity was mea-
sured after the addition of 3.5 mL scintillation mixture using
a LS5000TD liquid scintillation counter (Beckman Coulter).
The enzyme activity was expressed in units (1U¼ 1 mmol
of incorporated xylose per minute). To measure within the
linear range, cell culture supernant was diluted with 0.1 M
TriseHCl (pH 7.0) containing 1% (w/v) BSA.
DETERMINATION OF MICHAELISeMENTEN
CONSTANT (KM) AND VMAX
For the determination of the Km-values, various concen-
trations of the bFGF fragment (1e24) were incubated with
the diluted XT-I cell culture supernants and UDP-[14C]-D-xy-
lose under assay conditions as described above. The bFGF
peptide has one xylosylation site per molecule and a molec-
ular mass of 2553.86 g/mol. Km and Vmax were calculated
on the basis of nonlinear regression analysis.
STATISTICAL ANALYSIS
The distribution of the alleles of each single nucleotide
polymorphism (SNP) was tested for the HardyeWeinberg
equilibrium. Fisher’s two-tailed exact P test was used to
compare allele frequencies between patients and controls.
For normally distributed clinical characteristics, a compari-
son between the groups was performed by an unpaired Stu-
dent’s t test. For non-normally distributed variables
a ManneWhitney U test was used. The Spearman test
was applied for nonparametric correlations of dependencies
between XT activity and clinical characteristics. P values of
<0.05 were considered statistically signiﬁcant. For an agedependent analysis of allele frequencies patients aged 62
(25% percentile of whole cohort) and younger were com-
pared with the older OA patients.
Results
MUTATIONAL SCREENING AND GENOTYPING
With the intention to search for genetic alterations in the
XYLT-genes which were involved in the pathogenesis of
OA, we screened all 23 exons, exon/intron junctions and
parts of the 5#- and 3#-untranslated regions (UTRs) of these
genes. In total 9.4 kbp was screened in each individual.
This mutational analysis revealed a total of 25 different
DNA variations, 12 in XYLT-I and 13 in XYLT-II (Table II).
Twelve of them were located in the introns and the 5#-
UTR. Seven of the 13 exon nucleotide substitutions inﬂu-
ence the corresponding amino acid sequence (two in XT-I
and ﬁve in XT-II). Here we detected for the ﬁrst time ﬁve
new intron variations in XYLT-I and the amino acid ex-
change p.R406C in exon 6 of XYLT-II, all others were de-
scribed elsewhere19. The allelic frequencies of the OA
patients and the non-OA control group of 15 variations
(ﬁve in XYLT-I and 10 in XYLT-II) were determined using
DHPLC or RFLP. Here, we found a further new amino
acid exchange in exon 8 of XYLT-I (c.1655T >G; p.I552S)
in a blood donor (Table II).
COMPARISON OF ALLELE FREQUENCIES IN OA
PATIENTS AND CONTROLS
The genotype distribution of these 15 variations is similar
between the OA patients and the controls (Table II) and be-
tween men and women (data not shown). The OA patients
were subdivided into two groups (Table IV) in dependency
of their age with the intention to detect variations which
are associated with an early disease onset. The compari-
son of the allele frequencies of the 12 younger patients
(mean age 55.9 5.7 years) with those of the older patients
(mean age 72.3 5.7 years) revealed a signiﬁcantly differ-
ent distribution of the c.1569C > T variation in exon 8 of
XYLT-II with a higher frequency in the younger patients
(79% vs 39%; P¼ 0.0009). Furthermore, we detected also
a signiﬁcantly higher frequency of this SNP when compar-
ing the younger patients and the control group with the
mean age of 39.7 19.3 years (79% vs 53%; P¼
0.0165). We analyzed also whether the age of diagnosis
is associated with the appearance of any variation
(Table IV). Therefore, we subdivided the patients into two
groups, the ﬁrst one included 17 patients with an age of di-
agnosis under 60 years and the other contained 32 patients
Table IV
Allelic frequencies of the SNP c.1569C > T in the XYLT-II gene in
the OA patient group (n¼ 49) according to their age and the age
of diagnosis and in the control group (n¼ 111)
Subgroup n c.1569C > T P-value
OA patients: age< 62 years 12 19/24 0.0009
OA patients: age 63 years 37 29/74
OA patients: age< 62 years 12 19/24 0.0165
Control group: age 18e68 years 111 117/222
OA patients: age of diagnosis
< 60 years
17 23/34 0.0105
OA patients: age of diagnosis
 60 years
32 25/64
446 S. Scho¨n et al.: Xylosyltransferases in osteoarthritiswith an age of diagnosis over 60 years. We detected a sig-
niﬁcantly higher allelic frequency of the c.1569C > T varia-
tion in the ﬁrst group (68% vs 39%; P¼ 0.0105).
GENOTYPEePHENOTYPE CORRELATION IN OA PATIENTS
In order to analyze the implication of frequent SNPs (fre-
quency over 15%; four in XYLT-I and ﬁve in XYLT-II) with
clinical characteristics in OA patients, we investigated the
duration of OA, the number of joints affected, XT activity
and the effect on hip or knee and the appearance of mutant
genotypes. Therefore we compared whether these charac-
teristics differ in mutant and wt allele carriers in OA patients.
However, we could not ﬁnd any further signiﬁcant associa-
tion for any characteristic or any variation (data not shown)
than the associations for age and age of diagnosis as de-
scribed above.
SERUM XT ACTIVITY IN OA PATIENTS AND BLOOD DONORS
We assayed the XT activity in serum samples from 49 pa-
tients (21 males/28 females) suffering from OA and a non-
OA control group (203 males/119 females) with silk ﬁbroin
as the acceptor. XT activities (all values are given as
meanSD; 90% range) in the serum of the controls (men
1.00 mU/L 0.30, 0.48e1.52 mU/L; women 0.84 mU/
L 0.17, 0.61e1.14 mU/L) and of the OA patients (men
1.06 mU/L 0.17, 0.85e1.39 mU/L; women 1.02 mU/
L 0.13, 0.82e1.24 mU/L) were normally distributed
(Fig. 1). XT activity in the serum of the male patients and
the male control group showed no signiﬁcant difference
(P¼ 0.37). XT activities in serum specimens from female
patients were signiﬁcantly increased compared to female
blood donors (P< 0.0001). Furthermore, we investigated
whether the XT activity in the sera of patients depends on
the duration of OA. This analysis showed a signiﬁcantly
Fig. 1. Mean values and 90% ranges of serum XT activities in OA
patients and healthy blood donors are shown. The mean values of
the male OA patients were within the same range as the values of
the male blood donors. Serum XT activities of female OA patients
are signiﬁcantly elevated in comparison to those in female blood
donors (P< 0.0001).positive correlation of duration of the disease (P¼ 0.032;
r¼ 0.3069).
EXPRESSION OF WT AND MUTANT XT-I FORMS IN THE HIGH
FIVE INSECT CELLS
The soluble histidine and V5-tagged recombinant XT-I
(rXT-I) form of human XT-I lacking the cytoplasmatic tail,
the transmembrane region and a part of the stem region
(amino acids 1e148) were expressed in the High Five in-
sect cells. The highly active enzyme was secreted into the
supernant. We generated expression vectors of the de-
tected XYLT-I single amino acid mutants (c.1154C > T;
c.1655T >G; c.1883G > A and c.2675G > A) from the origi-
nal vector to analyze the enzymatic abilities of these altered
enzymes. The wt and mutant enzymes of XT-I were ex-
pressed in the High Five insect cells. The expression of
all enzymes was controlled in the Western blot using anti-
V5 antibodies (Fig. 2). The proteins containing the amino
acid exchanges were found to be expressed in insect cells
at similar levels as the wt and gave a single band of approx-
imately 90 kDa.
CHARACTERIZATION OF rXT-I AND MUTANTS
FOR CATALYTIC ACTIVITY
The activities of the wt and the mutant proteins were de-
termined in XT-I activity assays using the bFGF fragment
(1e24). All mutants expressed in the High Five insect cells
are enzymatically active. The comparison of the activities
between the mutants and the wt is presented in Fig. 2. It
was pointed out that the c.1883G > A (p.R628H; exon 9)
and c.2675 G > A (p.R892Q; exon 12) mutants did not affect
catalytic activity of recombinant human XT-I. The amino
acid exchanges at the positions c.1154C > T (p.P385L;
exon 5) and c.1655T >G (p.I552S; exon 8) resulted in
Fig. 2. Relative activities of wt XT-I and amino acid mutants. Re-
combinant XT-I amino acid mutants and the wt were expressed
in the High Five insect cells and detected by Western blotting using
anti-V5 antibodies and XT-I activity was determined. The bar chart
indicates the percentage XT-I activity relative to the rXT-I wt with
error bars representing the SD.
447Osteoarthritis and Cartilage Vol. 14, No. 5decreased enzymatic function. Compared with the wt XT-I,
the p.P385L-mutant has 84% enzymatic activity and the
p.I552S-mutant has 74% activity. We determined for these
two mutants Km- and Vmax-values. Kinetic analysis of the
wt secretory XT-I and the two mutants was performed using
the bFGF fragment (1e24) with various concentrations. The
Km-values of the recombinant wt and mutants of XT-I were
determined as 18.1 mM (wt), 41.1 mM (c.1154C > T) and
38.2 mM (c.1655T) (Table V). These results indicate a re-
duced substrate binding afﬁnity for the amino acid mutants.
Discussion
OA is the most common musculoskeletal disorder world-
wide3 and various factors are involved in its pathogenesis.
The central hallmark is cartilage degeneration and the
loss of PGs. These observations let us suppose that en-
zymes responsible for the homeostasis of cartilage PGs
might be involved in the development of OA. Therefore
we analyzed the XYLT-genes for genetic variations, the in-
ﬂuence of XYLT-I amino acid exchanges of the enzymatic
activity and the XT activity in OA patients. Applying the
DHPLC technique we identiﬁed 25 different XYLT-varia-
tions in our patients and a further one in a male blood donor
(XYLT-I; c.1655T >G; p.I552S). Most of the exon variations
are synonymous, only eight SNPs change the amino acid
sequence. Alterations in the amino acids were rare (5%)
with the exception of the p.T305R and p.T801R SNPs in
XT-II. All of the rare exchanges, apart from p.A115S in
exon 1 of XT-I, were only detected in a heterozygous state.
This result and the absence of nonsense mutations, dele-
tions and insertions in the exons let us conclude that the
function of the XTs is essential for life because PGs play im-
portant roles in many physiological processes. Until now no
disorders involving a mutation of XT-I or XT-II have been
known. The homozygous exchange from alanine to serine
is located at the N-terminal region of the XT-I and not nec-
essary for enzymatic activity, as we could show with N-
terminal truncated variants expressed in insect cells (Mu¨ller,
personal communication). OA patients with this variation in
homozygous or heterozygous state have XT-I activities
within the normal range. With an aim to assess the thus
far detected heterozygous amino acid substitutions in XT-I
with regard to their inﬂuence on enzymatic function, we
used the High Five insect cell system for their recombinant
expression. This is a reliable method for the expression of
enzymatically active XT-I. The cell culture supernants con-
tained similar levels of wt and mutant XT-I. The recombinant
enzymes with the alteration p.R628H in exon 9 and
p.R892Q in exon 12 showed the same XT-I activity as the
wt enzyme. The mutations p.P385L in exon 5 and p.I552S
in exon 8 have only 84% and 74% of wt enzymatic activity,
respectively, when assayed in vitro. Their Michaelise
Menten constants were increased two-fold, indicating re-
duced substrate binding afﬁnity. We compared the amino
Table V






XT-I; wt 18.10 0.96 3.58 0.18 0.20
XT-I; c.1154C > T 41.16 2.15 7.24 0.08 0.18
XT-I; c.1655T >G 38.25 0.56 4.06 0.11 0.14
*Values are shown as meansSD.acid sequences at the mutated positions of XT-I from hu-
man, mouse, rat, Drosophila, C. elegans, mosquito and puf-
ferﬁsh, and the sequences of XT-II from human and rat. The
amino acids at the corresponding position to p.P395L are
also imino acids, neutral or basic and therefore the ex-
change into the aliphatic amino acid leucine with reduced
polarity can inﬂuence the structure of the enzyme and re-
sults in reduced substrate binding afﬁnity. The p.I552S mu-
tation, where an aliphatic amino acid which was found in all
investigated species was replaced by a hydrophil amino
acid, might have the same consequences.
Interestingly, people with these mutations in heterozy-
gous state have XT activities within normal range (female
OA patient with c.1154C > T, 1.0 mU/L; male blood donor
with c.1655T >G, 0.91 mU/L). These results suggest that
the slight reduction in XT-I activity in vitro could be compen-
sated by the second wt allele under physiological condi-
tions. This might be a reason for why they were only
found in heterozygous state. It is possible that the homozy-
gous form results, as shown in vitro, in reduced XT-I activity
and that this could result in alterations in PG metabolism.
A detailed analysis of the detected amino acid exchanges
in the XYLT-II gene product is not yet possible as the enzy-
matic function of XT-II is not clariﬁed. We only can hypoth-
esize that the frequent amino acid substitutions in XT-II
(p.T305R and p.T801R) did not inﬂuence the enzymatic
activity to a great extent because they were found in OA
patients and in controls in homozygous and heterozygous
states.
The higher frequency of the c.1569C > T in exon 8 of
XYLT-II in younger OA patients and in patients with an early
disease onset suggests that this SNP is associated with
a genetic predisposition of OA. We can only assume in
what way this synonymous variation is associated with
OA. Probably, this SNP is a marker-SNP and associated
with further variations which are responsible for alterations
in AC homeostasis. Such variations could be located in
the introns or in promoter regions and could function as en-
hancer, silencer or transcription binding sites and affect
gene transcription or RNA splicing. The correlation of the
genotypes (XYLT-I and XYLT-II SNPs with a frequency of
more than 15%) with duration of OA, joint involvement, XT
activity and the effect on hip or knee phenotype between
patients with the mutant alleles in heterozygous or homozy-
gous state and patients with the wt alleles did not reveal
associations with these characteristics.
XT-I is the initial enzyme in the biosynthesis of the GAG
chains in CSPGs. We have shown previously that the serum
XT activity is a biochemical marker for ﬁbrotic tissue remod-
eling as it reﬂects the PG biosynthesis rate15,26. The human
XT-I has a type II transmembrane structure15,21 and xylosy-
lation of core proteins takes place in the endoplasmatic retic-
ulum (ER) or in the Golgi apparatus. The presence of
a soluble XT-I in the serum after shedding and secretion
makes XT-I a potential biochemical marker for an altered
PGmetabolism15,16,26. Here we found a signiﬁcant elevation
of the XT activity with increasing duration of OA and we
detected a signiﬁcantly higher XT serum activity in female
OA patients compared with female blood donors. The higher
level of XT serum activity is not associated with any of the
detected XYLT-I or XYLT-II variations. The increasing XT
activity with the duration of the disease could be an indicator
for an incomplete intracellular retention of XT caused by an
altered metabolism in the Golgi apparatus resulting in higher
proteolytic cleavage of membrane bound XT by an endoge-
nous protease and a higher release of XT into the serum. It
has been speculated that proteolysis within the stem region
448 S. Scho¨n et al.: Xylosyltransferases in osteoarthritisand release of the catalytic domain might be a mechanism of
downregulating cellular activity27. The higher activity in OA
women compared to that in female blood donors might be
the result of the longer duration of the disease in women in-
cluded in our study (Table I). The identiﬁcation and charac-
terization of the promoter region, the proteolytic enzyme
and the cleavage site of XT-I might be necessary for the un-
derstanding of the biochemical reasons for this high XT activ-
ity. Furthermore, it might be useful to investigate if the serum
XT activity is a suitable marker for staging andmonitoring the
progression of AC damage in OA.
In summary, the results of our study are the detection of 25
genetic variations inGermanOApatients and the association
of c.1569T-allele inXYLT-IIwith anearly onset ofOA. Further
studies on the correlation of the XT activity upregulation and
disease duration and the genetic association of the c.1569-
SNP in XYLT-II with OA might be useful for the detailed un-
derstanding of the pathological mechanisms causing OA.
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